Clinical Trials

Ramipril has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4, primarily targeting cardiovascular, renal, and metabolic disorders alongside exploratory applications such as radiation-induced cognitive decline and systemic lupus erythematosus. Sponsored by academic medical centers, research institutes, and pharmaceutical companies, these studies represent diverse recruitment statuses, including completed, recruiting, active, and terminated. Overall, this broad portfolio underscores ramipril's extensive evaluation across primary cardiovascular indications and secondary disease contexts.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05508035 RECRUITING
Heart Failure With Moderately Reduced Ejection Fraction
John Paul II Hospital, Krakow
 2023-07-13 PHASE3
NCT06562582 RECRUITING
Myocardial Infarct
Vastra Gotaland Region
 2025-01-06 PHASE4
NCT03770936 RECRUITING
Liver Fibroses
Sherief Abd-Elsalam
 2018-10-01 PHASE3
NCT02842424 RECRUITING
Peripheral Arterial Disease
University of Nebraska
 2016-02-25 PHASE4
NCT05030818 RECRUITING
Coronary Artery Disease
Fundación EPIC
 2022-10-14 PHASE4
NCT07259512 RECRUITING
Chronic Kidney Disease; Heart Failure With Reduced Ejection Fraction (HFrEF)
Evi Liliek Wulandari
 2025-06-30 PHASE4
NCT04173949 ACTIVE_NOT_RECRUITING
Persistent Developmental Stuttering
HaEmek Medical Center, Israel
 2020-03-15 PHASE3
NCT07184918 COMPLETED
Contrast-Induced Nephropathy; Coronary Angiography; Acute Kidney Injury
Tanta University
 2024-02-01
NCT06304896 UNKNOWN
Chemotherapy Induced Systolic Dysfunction
Arab Contractors Medical Centre
 2024-05-01 PHASE1
NCT03475186 COMPLETED
Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation
Wake Forest University Health Sciences
 2019-03-25 PHASE2
NCT07023016 COMPLETED
Acute Decompensated Heart Failure (ADHF); Chronic Kidney Disease (CKD)
National Heart Institute, Egypt
 2023-11-01 PHASE2; PHASE3
NCT05133050 NOT_YET_RECRUITING
Alport Syndrome
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
 2022-01-01
NCT03991910 UNKNOWN
Rheumatic Heart Disease; Mitral Stenosis; Rheumatic Mitral Stenosis; Fibrosis; Heart; ACE Inhibitor
Indonesia University
 2019-06-27 PHASE3
NCT05271448 UNKNOWN
Contrast-induced Nephropathy; Chronic Kidney Diseases; Ischemic Heart Disease
An-Najah National University
 2021-06-01
NCT05849766 COMPLETED
Dilated Cardiomyopathy
October 6 University
 2023-04-27 PHASE3
NCT06104423 COMPLETED
Hypertension
Menarini International Operations Luxembourg SA
 2023-10-02 PHASE4
NCT07315139 COMPLETED
Pentoxifylline; Inflammatory Markers; Non-Diabetic; Chronic Kidney Disease
Ain Shams University
 2023-02-01
NCT05685277 COMPLETED
Bioequivalence
Pharmtechnology LLC
 2022-12-28 PHASE1
NCT05438316 COMPLETED
Bioequivalence
Pharmtechnology LLC
 2022-06-17 PHASE1
NCT05438316 Completed
Bioequivalence
Pharmtechnology LLC|Ligand Research LLC
 2022-06-17 Phase 1
NCT02236806 UNKNOWN
Breast Cancer; Cardiotoxicity
Azienda Ospedaliero-Universitaria Careggi
 2015-07 PHASE3
NCT03201185 UNKNOWN
Transcatheter Aortic Valve Replacemen; Angiotensin-Converting Enzyme Inhibitors
Hospital Clínico Universitario de Valladolid
 2018-02-10 PHASE4
NCT03715998 COMPLETED
Myocardial Infarction
Quantum Genomics SA
 2019-06-04 PHASE2
NCT04366050 COMPLETED
COVID-19
University of California, San Diego
 2020-05-11 PHASE2
NCT02924727 COMPLETED
Acute Myocardial Infarction
Novartis Pharmaceuticals
 2016-12-09 PHASE3
NCT02499822 COMPLETED
Hypertension; High Blood Pressure Variability
Istituto Auxologico Italiano
 2015-10 PHASE4
NCT04143412 UNKNOWN
Diabetic Nephropathy Type 2; Microalbuminuria Due to Type 2 Diabetes Mellitus
Beni-Suef University
 2019-02-04 PHASE2
NCT02008786 TERMINATED
Coronary Artery Dissection, Spontaneous
Cardiology Research UBC
 2014-06 PHASE4
NCT04262765 COMPLETED
Healthy Volunteers
Midas Pharma GmbH
 2019-02-23 PHASE1
NCT04582097 COMPLETED
Hemodialysis
Ain Shams University
 2018-12-01 PHASE2; PHASE3
NCT03475186 Active not recruiting
Glioblastoma|Radiotherapy; Complications|Cognitive Decline|Chemoradiation
Wake Forest University Health Sciences|National Cancer Institute (NCI)
 2019-03-25 Phase 2
NCT01485978 COMPLETED
Renal Insufficiency, Chronic
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
 2012-03 PHASE3
NCT01922141 WITHDRAWN
Hypertension
Novartis Pharmaceuticals
 2015-05 PHASE4
NCT03414723 COMPLETED
Diabetes Mellitus; Healthy Subjects
Sanofi
 2018-01-15 PHASE1
NCT03440177 Recruiting
Obesity Morbid
Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital
 2018-01-02 --
NCT02632747 COMPLETED
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity
Boehringer Ingelheim
 2016-05-10 PHASE2
NCT02832973 COMPLETED
Hypertension Resistant to Conventional Therapy
Sao Jose do Rio Preto Medical School
 2015-09 PHASE4
NCT02791958 UNKNOWN
Hypertension
Ferrer Internacional S.A.
 2016-03 PHASE2
NCT02525081 COMPLETED
Microvascular Angina
Bispebjerg Hospital
 2015-07 PHASE4
NCT01856361 TERMINATED
Oligospermia; Teratospermia; Asthenozoospermia; Male Infertility
Weill Medical College of Cornell University
 2013-07
NCT00985322 COMPLETED
Left Ventricular Hypertrophy; Hypertension
Mario Negri Institute for Pharmacological Research
 2009-05 PHASE3
NCT01504828 COMPLETED
Left Ventricular Function Systolic Dysfunction; Left Ventricular Function Diastolic Dysfunction; Ageing
Newcastle-upon-Tyne Hospitals NHS Trust
 2012-07
NCT01968759 COMPLETED
Chronic Kidney Disease
Mario Negri Institute for Pharmacological Research
 2013-10 PHASE2
NCT00878969 TERMINATED
Oxidative Stress; Endothelial Dysfunction
Vanderbilt University
 2010-01 PHASE3
NCT00933231 COMPLETED
Kidney Transplantation
Astellas Pharma Inc
 2009-08-17 PHASE3
NCT02029118 COMPLETED
Stable Angina Pectoris
Chengdu University of Traditional Chinese Medicine
 2012-10 EARLY_PHASE1
NCT01078363 COMPLETED
Cardiac Allograft Vasculopathy
Stanford University
 2009-06
NCT00736294 TERMINATED
Atrial Fibrillation; Atrial Flutter
Centre Hospitalier Universitaire de Saint Etienne
 2008-07 PHASE3
NCT02901977 COMPLETED
Hypertension
Karolinska Institutet
 2011-03 PHASE4
NCT00574834 TERMINATED
Metabolic Syndrome
University of Maryland, Baltimore
 2007-03 EARLY_PHASE1
NCT01743014 UNKNOWN
Diabetes Type 2; Diabetic Nephropathy; Vascular Disease
AHEPA University Hospital
 2012-07 PHASE4
NCT02570581 COMPLETED
Healthy
Centre Hospitalier Universitaire de Nice
 2014-06 PHASE1
NCT01437371 COMPLETED
Heart Failure
University Hospital, Clermont-Ferrand
 2011-08 PHASE3
NCT03011775 COMPLETED
Adverse Effect; Atherosclerosis, Coronary; Insulin Resistance Syndrome
Ukrainian Medical Stomatological Academy
 2012-11 PHASE4
NCT01321255 COMPLETED
Myocardial Infarction
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
 2012-01 PHASE3
NCT01234922 TERMINATED
Hypertension; Unspecified Adult Solid Tumor, Protocol Specific
Wake Forest University Health Sciences
 2011-02 PHASE2
NCT00502242 COMPLETED
Kidney Transplant
Pfizer
 2007-12 PHASE4
NCT03979976 COMPLETED
Systemic Lupus Erythematosus
Federal University of São Paulo
 2011-03 PHASE2; PHASE3
NCT01037530 COMPLETED
Intermittent Claudicants
Hull University Teaching Hospitals NHS Trust
 2010-12 PHASE4
NCT02729441 COMPLETED
Diabetes; Microalbuminuria
Sunnybrook Health Sciences Centre
 2010-04 PHASE3
NCT01743014 Unknown status
Diabetes Type 2|Diabetic Nephropathy|Vascular Disease
AHEPA University Hospital|Aristotle University Of Thessaloniki
 2012-07 Phase 4
NCT01362218 TERMINATED
Elevated LDL Cholesterol
Ferrer Internacional S.A.
 2010-10 PHASE2
NCT01180413 COMPLETED
Essential Hypertension; High Blood Pressure
Aarhus University Hospital
 2010-12 PHASE4
NCT00732069 COMPLETED
End Stage Renal Failure on Dialysis; Complication of Hemodialysis
Vanderbilt University
 2008-08 PHASE2
NCT01302899 TERMINATED
Non-diabetic Nephropathy
Novartis Pharmaceuticals
 2011-01 PHASE2
NCT00535925 COMPLETED
Diabetic Nephropathy
University of Campania Luigi Vanvitelli
 2005-10 PHASE4
NCT00607672 COMPLETED
Coronary Artery Disease; Angiotensin Converting Enzyme; Angiotensin Receptor Blockers; Cardiopulmonary Bypass; Fibrinolysis; Inflammation
Vanderbilt University
 2006-08 PHASE4
NCT00681226 COMPLETED
Peripheral Arterial Disease
Bayside Health
 2008-01 PHASE4
NCT00980785 COMPLETED
Alzheimer's Disease; Hypertension
University of Wisconsin, Madison
 2009-04-09 PHASE4
NCT01230034 UNKNOWN
Hypertension; Type 2 Diabetes Mellitus; Microalbuminuria
University of Pavia
 2010-10 PHASE3
NCT01004705 TERMINATED
Elevated LDL Cholesterol
Ferrer Internacional S.A.
 2009-09 PHASE2
NCT01284621 COMPLETED
Healthy
Boehringer Ingelheim
 2011-01 PHASE1
NCT00923156 COMPLETED
Heart Failure
Novartis Pharmaceuticals
 2009-05 PHASE2
NCT01042392 COMPLETED
Essential Hypertension
Novartis
 2009-11 PHASE4
NCT01052272 COMPLETED
Diabetes
University of Alabama at Birmingham
 2005-07 PHASE2; PHASE3
NCT01005290 TERMINATED
Hypertension
Ferrer Internacional S.A.
 2009-10 PHASE2
NCT00437463 COMPLETED
Glomerulonephritis
Sanofi
 2004-07 PHASE3
NCT00141778 COMPLETED
Atrial Fibrillation
Vanderbilt University
 2005-04 PHASE2; PHASE3
NCT01225445 COMPLETED
Biopsy-confirmed IgA Nephropathy; Proteinuria Less Than 0.5 g Per Day; Normal Blood Pressure; Serum Creatinine Below 120 Umol/l
Chinese University of Hong Kong
 2002-04 PHASE3
NCT00729365 TERMINATED
Type 1 Diabetes
Northwestern University
 2008-07 PHASE3
NCT03099213 COMPLETED
Coronary Artery Disease
Sanofi
 2008-11-01 PHASE4
NCT00657865 COMPLETED
Healthy
Medical University of Vienna
 2008-03 PHASE4
NCT01038895 UNKNOWN
Hypertension; Type 2 Diabetes
University of Pavia
 2009-11 PHASE4
NCT00939588 COMPLETED
Hypertension
Novartis Pharmaceuticals
 2009-07 PHASE2
NCT00631917 COMPLETED
Hypertension
Novartis
 2008-02 PHASE4
NCT00841880 COMPLETED
Hypertension
Sanofi
 2009-01 PHASE4
NCT00292162 COMPLETED
Chronic Heart Failure; Atrial Fibrillation
NHS Greater Glasgow and Clyde
 2007-01
NCT00542269 TERMINATED
Hypertension With Metabolic Syndrome
Novartis
 2008-03 PHASE4
NCT00819845 UNKNOWN
Duchenne Muscular Dystrophy; Becker Muscular Dystrophy
Catholic University, Italy
 2008-12 PHASE4
NCT00608465 TERMINATED
Metabolic Syndrome X
Vanderbilt University
 2006-05 PHASE4
NCT00760214 COMPLETED
Hypertension
Takeda
 2008-01 PHASE3
NCT00893425 COMPLETED
Proteinuria; Diabetic Nephropathy; Chronic Kidney Disease
Gulhane School of Medicine
 2008-01 PHASE4
NCT01703234 COMPLETED
Proteinuria; Diabetic Nephropathy; Chronic Kidney Disease
Gulhane School of Medicine
 2008-01 PHASE4
NCT00772577 COMPLETED
Hypertension
Novartis
 2008-08 PHASE4
NCT00391846 COMPLETED
Heart Failure; Ventricular Dysfunction, Left
AstraZeneca
 2006-10 PHASE4
NCT00750308 COMPLETED
Metabolic Syndrome
Vanderbilt University
 2006-12
NCT00473174 COMPLETED
Hypertension
University of Vigo
 2007-03 PHASE4
NCT00443794 COMPLETED
Cardiovascular Diseases
St. John's Research Institute
 2007-03
NCT00702936 UNKNOWN
Acute Coronary Syndrome; Myocardial Infarction; Coronary Disease
Catholic University of the Sacred Heart
 2007-11 PHASE4
NCT00529451 COMPLETED
Hypertension
Novartis
 2007-09 PHASE3
NCT00153101 COMPLETED
Cardiovascular Diseases
Boehringer Ingelheim
 2001-11 PHASE4
NCT00738660 COMPLETED
Diabetic Nephropathy
Post Graduate Institute of Medical Education and Research, Chandigarh
 2007-02 PHASE3
NCT00770497 COMPLETED
Inflammation; Hypertension
Takeda
 2007-03 PHASE2
NCT00507845 COMPLETED
Hypertension
Sanofi
 2007-06 PHASE4
NCT00674596 COMPLETED
Diabetes; Proteinuria; Renin Angiotensin System
Gulhane School of Medicine
 2006-01 PHASE4
NCT00368277 COMPLETED
Hypertension
Novartis Pharmaceuticals
 2006-09 PHASE3
NCT02214966 COMPLETED
Healthy
Boehringer Ingelheim
 2007-10 PHASE1
NCT00389519 TERMINATED
Hypertension
Pfizer
 2006-10 PHASE3
NCT02215005 COMPLETED
Healthy
Boehringer Ingelheim
 2007-06 PHASE1
NCT02214979 COMPLETED
Healthy
Boehringer Ingelheim
 2007-03 PHASE1
NCT02214992 COMPLETED
Healthy
Boehringer Ingelheim
 2007-03 PHASE1
NCT00281593 COMPLETED
Hypertension
Boehringer Ingelheim
 2006-04 PHASE3
NCT00310778 COMPLETED
Healthy
Assistance Publique - Hôpitaux de Paris
 2006-03 PHASE1
NCT00355589 COMPLETED
Hypertension; Blood Pressure, High
Pfizer
 2006-07 PHASE3
NCT00200694 TERMINATED
Heavy Proteinuria
Nantes University Hospital
 2005-03 PHASE4
NCT00343551 COMPLETED
Essential Hypertension
Novartis
 2006-05 PHASE3
NCT01115426 COMPLETED
IGA Glomerulonephritis
University Magna Graecia
 1997-01 PHASE4
NCT00879476 COMPLETED
Healthy
Ranbaxy Laboratories Limited
 2007-01
NCT00879788 COMPLETED
Healthy
Ranbaxy Laboratories Limited
 2006-10
NCT00367939 COMPLETED
Hypertension
Novartis
 2005-12 PHASE3
NCT00219063 COMPLETED
Hypertension
Novartis
 2005-02 PHASE3
NCT00054938 COMPLETED
Systemic Lupus Erythematosus; Lupus
Brigham and Women's Hospital
 2003-03 PHASE2
NCT00095290 COMPLETED
Albuminuria
Bristol-Myers Squibb
 2004-09 PHASE4
NCT01164774 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2005-10 PHASE1
NCT01164761 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2005-09 PHASE1
NCT00325806 COMPLETED
Hypertension
Sanofi
 2000-05 PHASE4
NCT00219089 COMPLETED
Hypertension, Diabetes Mellitus
Novartis
 2004-11 PHASE3
NCT01402479 COMPLETED
Migraine With Hypertension
Seoul National University Hospital
 2004-10 PHASE2
NCT01053910 COMPLETED
Atherosclerosis
Sanofi
 2003-10 PHASE4
NCT00268619 COMPLETED
Myocardial Ischemia
Sanofi
 2004-06 PHASE3
NCT00702260 COMPLETED
Hypertension
Roxane Laboratories
 2005-01
NCT00702091 COMPLETED
Hypertension
Roxane Laboratories
 2005-01
NCT00946465 COMPLETED
Hypertension
Sandoz
 2004-10 PHASE1
NCT00946621 COMPLETED
Hypertension
Sandoz
 2004-10 PHASE1
NCT00829452 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2004-08 PHASE1
NCT00863915 COMPLETED
Healthy
Actavis Inc.
 2004-10 PHASE1
NCT00829530 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2004-08 PHASE1
NCT00864162 COMPLETED
Healthy
Actavis Inc.
 2004-09 PHASE1
NCT00828321 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2004-08 PHASE1
NCT00864448 COMPLETED
Healthy
Actavis Inc.
 2004-10 PHASE1
NCT00679653 COMPLETED
Obesity; Hypertension
Abbott
 2002-02 PHASE3
NCT00274599 COMPLETED
Hypertension
Boehringer Ingelheim
 2002-10-09 PHASE4
NCT00274612 COMPLETED
Hypertension
Boehringer Ingelheim
 2002-10 PHASE4
NCT00480805 COMPLETED
Type 2 Diabetes Mellitus; Hypertension
Organon and Co
 2001-08-08 PHASE3
NCT04364139 COMPLETED
Hypertensive Nephrosclerosis; Chronic Renal Insufficiency
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 1995-02-01 PHASE3
NCT00356395 COMPLETED
Hypertension
Gachon University Gil Medical Center
 2003-08 PHASE4
NCT00208221 TERMINATED
Hypertension; Type 2 Diabetes; Albuminuria
Institut de Recherches Cliniques de Montreal
 2006-08 PHASE3
NCT00273533 COMPLETED
Arthritis, Rheumatoid
University of Zurich
 2004-06 PHASE2; PHASE3
NCT00489229 COMPLETED
Diabetes; Impaired Glucose Tolerance
Universiti Sains Malaysia
 2002-10 PHASE3
NCT00366119 UNKNOWN
Essential Hypertension
Pacific Pharmaceuticals
 2006-06 PHASE4
NCT00005928 COMPLETED
Atherosclerosis; Coronary Disease; Vasculitis
National Heart, Lung, and Blood Institute (NHLBI)
 2000-06 PHASE2
NCT00140647 COMPLETED
Atherosclerosis; Impaired Glucose Tolerance; Isolated Impaired Fasting Glucose; Cardiovascular Disease
Gerstein, Hertzel, MD
 2001-07 PHASE3
NCT00044265 COMPLETED
Hypertension
Pfizer
 2002-07 PHASE4
NCT00160160 COMPLETED
Hypertension; Type 2 Diabetes
Solvay Pharmaceuticals
 2004-10
NCT00095654 COMPLETED
Impaired Glucose Tolerance; Cardiovascular Disease; Glucose Metabolism Disorders
Gerstein, Hertzel, MD
 2001-07 PHASE3
NCT00240422 COMPLETED
Diabetes Mellitus, Type 2; Hypertension
Boehringer Ingelheim
 2003-02 PHASE4
NCT00517322 UNKNOWN
Left Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function; Renin Angiotensin System
Università degli Studi dell'Insubria
 2007-08 PHASE4
NCT00168467 COMPLETED
Peripheral Arterial Disease
Baker Heart Research Institute
 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-07-31)

Check the Ramipril product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ramipril potently binds to and inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 nM, thereby suppressing the enzymatic conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This reduction in angiotensin II decreases systemic vascular resistance and relaxes arterial smooth muscle, providing the therapeutic basis for its broad clinical evaluation in hypertension, heart failure, and diabetic nephropathy.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.